Longboard Pharmaceuticals
Clinical trials sponsored by Longboard Pharmaceuticals, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for Hard-to-Treat seizures: phase 3 trial launches Results expected Oct 2026 (estimated)
- New hope for dravet syndrome: phase 3 trial of LP352 aims to cut seizure frequency Results expected Dec 2026 (estimated)